Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 314.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 169,043 shares of the medical device company's stock after buying an additional 128,294 shares during the period. Tudor Investment Corp ET AL owned 0.26% of Tandem Diabetes Care worth $6,089,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TNDM. AlphaQuest LLC grew its stake in Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares during the period. Jones Financial Companies Lllp grew its position in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after purchasing an additional 748 shares during the period. McIlrath & Eck LLC acquired a new stake in shares of Tandem Diabetes Care in the third quarter valued at about $52,000. Assetmark Inc. increased its stake in shares of Tandem Diabetes Care by 77.5% during the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after purchasing an additional 1,101 shares during the last quarter.

Tandem Diabetes Care Trading Up 3.3 %

TNDM traded up $0.71 on Tuesday, hitting $22.00. The company had a trading volume of 398,561 shares, compared to its average volume of 1,492,983. The company's fifty day moving average price is $18.56 and its 200 day moving average price is $28.43. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The firm has a market cap of $1.47 billion, a P/E ratio of -11.38 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same quarter in the prior year, the company posted ($0.65) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. As a group, equities analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.90% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TNDM shares. Morgan Stanley lowered Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $45.00 to $22.00 in a research note on Wednesday, March 5th. Barclays reduced their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. The Goldman Sachs Group decreased their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Piper Sandler dropped their target price on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Finally, Royal Bank of Canada decreased their price target on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $39.81.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.